InflaRx’s Gohibic (Vilobelimab) Receives the EC Approval for the Treatment of ARDS
Shots:
- The EC has approved (under exceptional circumstances) Gohibic to treat SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) adults on SoC (incl. systemic corticosteroids) & IMV (with/without ECMO)
- Approval was backed by results of the P-III (PANAMO) study assessing Gohibic vs. PBO among invasively mechanically ventilated COVID-19 patients in the ICU, which showed improvement in survival with a 23.9% relative reduction in 28-day all-cause mortality. The data was published in The Lancet Respiratory Medicine
- The marketing authorization for GOHIBIC is valid in all 27 EU member states, Iceland, Liechtenstein, and Norway. InflaRx is exploring commercial partnerships in the EU
Ref: InflaRx | Image: InflaRx
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
